Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. 2011

Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. L.joosten@aig.umcn.nl

Inhibition of histone deacetylases (HDAC) has been shown to modulate gene expression and cytokine production after stimulation with several stimuli. In the present study, the antiinflammatory effect of a potent HDACi, ITF2357, was explored in different experimental models of arthritis. In addition, the bone protective effect of ITF2357 was investigated in vitro. Treatment of acute arthritis (Streptococcus pyogenes cell wall [SCW] arthritis) with ITF2357 showed that joint swelling and cell influx into the joint cavity were reduced. Furthermore, the chondrocyte metabolic function was improved by treatment of ITF2357. The production of proinflammatory cytokines by synovial tissue was reduced after ITF2357 treatment. To examine the effect of HDAC inhibition on joint destruction, ITF2357 was applied to both rat adjuvant arthritis and mouse collagen type II arthritis. ITF2357 treatment both ameliorates the severity scores in arthritis models and prevents bone destruction. In an in vitro bone destruction assay, ITF2357 was highly effective at a dose of 100 nmol/L. In conclusion, inhibition of HDAC prevents joint inflammation and cartilage and bone destruction in experimental arthritis.

UI MeSH Term Description Entries
D007596 Joints Also known as articulations, these are points of connection between the ends of certain separate bones, or where the borders of other bones are juxtaposed. Joint
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D001847 Bone Diseases Diseases of BONES. Bone Disease,Disease, Bone,Diseases, Bone
D001862 Bone Resorption Bone loss due to osteoclastic activity. Bone Loss, Osteoclastic,Osteoclastic Bone Loss,Bone Losses, Osteoclastic,Bone Resorptions,Loss, Osteoclastic Bone,Losses, Osteoclastic Bone,Osteoclastic Bone Losses,Resorption, Bone,Resorptions, Bone
D002357 Cartilage Diseases Pathological processes involving the chondral tissue (CARTILAGE). Chondromalacia,Cartilage Disease,Chondromalacias
D003094 Collagen A polypeptide substance comprising about one third of the total protein in mammalian organisms. It is the main constituent of SKIN; CONNECTIVE TISSUE; and the organic substance of bones (BONE AND BONES) and teeth (TOOTH). Avicon,Avitene,Collagen Felt,Collagen Fleece,Collagenfleece,Collastat,Dermodress,Microfibril Collagen Hemostat,Pangen,Zyderm,alpha-Collagen,Collagen Hemostat, Microfibril,alpha Collagen
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001169 Arthritis, Experimental ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN. Adjuvant Arthritis,Arthritis, Adjuvant-Induced,Arthritis, Collagen-Induced,Arthritis, Adjuvant,Collagen Arthritis,Arthritides, Collagen,Arthritis, Collagen,Collagen Arthritides,Collagen-Induced Arthritides,Collagen-Induced Arthritis
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha

Related Publications

Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
November 1999, Journal of immunology (Baltimore, Md. : 1950),
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
January 1993, Agents and actions. Supplements,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
January 2022, Journal of ethnopharmacology,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
January 2016, Mediators of inflammation,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
February 2012, Clinical calcium,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
January 1998, Springer seminars in immunopathology,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
August 2013, Nature reviews. Rheumatology,
Leo A B Joosten, and Flavio Leoni, and Sajeda Meghji, and Paolo Mascagni
September 1999, Rheumatology (Oxford, England),
Copied contents to your clipboard!